Favipiravir Placebo

DRUG3 trials

Sponsors

Appili Therapeutics Inc., University College, London, Shanghai Vinnerna Biosciences Co., Ltd.

Conditions

COVID-19Moderate to Severe COVID-19SARS-CoV-2

Phase 2

Control of COVID-19 Outbreaks in Long Term Care

TerminatedNCT04448119

Appili Therapeutics Inc.COVID-19, SARS-CoV-2

Start: 2020-10-16End: 2021-10-30Updated: 2023-02-21

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals

CompletedNCT04499677

University College, LondonCOVID-19

Start: 2020-09-24End: 2022-01-17Updated: 2022-12-15

Phase 3

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

TerminatedNCT05279235

Shanghai Vinnerna Biosciences Co., Ltd.Moderate to Severe COVID-19

Start: 2022-03-14End: 2022-12-15Updated: 2023-02-08

Related Papers

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

PLoS Medicine2022-10-1931 citations

Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.

2021-11-066 citations

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial.

2021-07-2812 citations

Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.

2021-03-0812 citations